Vertex Pharmaceuticals (VRTX) FCF Margin (2009 - 2026)

Vertex Pharmaceuticals' FCF Margin history runs 18 years deep, the most recent figure standing at 43.35% for Q1 2026.

• On a quarterly basis, FCF Margin rose 1525.0% year-over-year to 43.35% in Q1 2026; TTM through Mar 2026 was 30.37%, a 4163.0% increase from a year earlier, with the FY2025 full-year figure at 26.61%, up 3378.0% from the prior year.
• FCF Margin climbed to 43.35% in Q1 2026 per VRTX's latest filing, from 10.93% in the prior quarter.
• Across five years, FCF Margin topped out at 49.47% in Q2 2022 and bottomed at 144.49% in Q2 2024.
• The 5-year median for FCF Margin is 38.61% (2022), against an average of 25.16%.
• Across the five-year window, FCF Margin sank 18760 bps in 2024 and jumped 17577 bps in 2025, its largest moves.
• Year by year, FCF Margin stood at 45.37% in 2022, then tumbled by 85 bps to 7.01% in 2023, then jumped by 141 bps to 16.9% in 2024, then slumped by 35 bps to 10.93% in 2025, then surged by 297 bps to 43.35% in 2026.
• Per Business Quant, the three latest VRTX FCF Margin figures stand at 43.35% (Q1 2026), 10.93% (Q4 2025), and 37.04% (Q3 2025).